Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.46 |
| ▸ | CNR1 | P21554 | 9/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928016 | 0.98 | CNR2 (0.46) | CNR2CNR1ACKR3EPHX2CDK1 | |
| SCHEMBL926911 | 0.89 | CNR2 (0.47) | CNR2CNR1ACKR3PDE4BMAPT | |
| SCHEMBL926960 | 0.87 | CNR2 (0.45) | CNR2CNR1ACKR3KDM4EHPGD | |
| SCHEMBL926747 | 0.87 | CNR2 (0.51) | CNR2CNR1ACKR3ALDH1A1TSHR | |
| SCHEMBL930026 | 0.87 | CNR2 (0.62) | CNR2CNR1EPHX2PDE4BMAPT | |
| SCHEMBL928431 | 0.86 | CNR2 (0.53) | CNR2CNR1PDE4BMAPT | |
| SCHEMBL926772 | 0.86 | CNR2 (0.46) | CNR2CNR1ACKR3EPHX2CDK1 | |
| SCHEMBL927584 | 0.86 | CNR2 (0.52) | CNR2CNR1ACKR3PDE4BMAPT | |
| SCHEMBL928869 | 0.86 | CNR2 (0.59) | CNR2CNR1MAPT | |
| SCHEMBL927437 | 0.85 | CNR2 (0.45) | CNR2CNR1ALDH1A1PDE4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | claimed |
| WO-2008028093-A1 | COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | WO | claimed |
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | claimed |
| US-8598224-B2 | Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | CNR2 2/4885CNR1 1/4885ACKR3 566/4885 |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | CNR2 2/4885CNR1 1/4885ACKR3 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.